Prediction: The Trump Bull Market Is About to End -- but These Stocks Will Rise Anyway

The catalyst is the US/Israel attack on Iran and disruption through the Strait of Hormuz; headline PPI jumped 3.4% YoY (Feb, pre-conflict) while the S&P 500 Shiller CAPE is near its second-highest level since early 2000. US macro is weakening: Q4 2025 GDP slowed to 1.4% and payrolls fell by 92,000 in February, creating a Fed dilemma between inflation and jobs. The author flags defensive ideas: Berkshire Hathaway for cash/insurance/utilities exposure, Enbridge (5.2% dividend yield; 31-year dividend-increase streak) for energy/dividend income, and Vertex Pharmaceuticals for its CF franchise plus potential povetacicept accelerated filing in H1 2026 and an inaxaplin pivotal readout by year-end.

Analysis

The Iran shock materially raises the probability that energy-driven goods inflation re-accelerates over the next 3–9 months, not just as a pump-price effect but via freight, fertilizer, and petrochemical cost pass-throughs that hit margins across consumer staples and industrials. That transmission will push real short-term yields higher if the Fed resists cutting, compressing long-duration multiples (tech, consumer discretionary) and widening dispersion between cash-flow-stable names and high-PE growth.

Second-order winners include assets with idiosyncratic cash generation or embedded optionality: businesses that can reprice long-term contracts (midstream and regulated utilities), insurers that benefit from higher nominal rates but face claim volatility, and conglomerates with large cash stockpiles able to deploy into distress. But there are offsetting risks — pipelines see higher throughput but also faster permitting/regulatory scrutiny and FX exposure on CAD-denominated cashflows; drug developers with late-stage readouts face binary outcomes that correlate weakly with macro, creating ideal pair trade candidates.

Catalyst and risk sequencing is short-to-medium term: oil normalization within 30–90 days would reverse much of the inflation shock and allow multiples to re-expand, while sustained disruption >3 months forces a stagflationary regime where cyclical earnings collapse and quality/ dividend proxies outperform. Key data triggers to watch are the next two PPI/PCE prints, 2y/10y real yield moves, weekly jobless claims, and any indications of U.S. maritime chokepoint reopening — each will reprice both risk premia and the Fed path within weeks, not years.

Key Decisions for Investors

• Long ENB (2–4% portfolio) with a 12-month horizon: initiate size in tranches while hedging downside with a 9–12 month 10–15% OTM put; target 15–25% total return (incl. dividends) if oil remains elevated, trim if WTI < $70 within 90 days. Rationale: stable FCF + dividend cushion vs oil upside; hedge caps downside to option premium.
• Core long in BRKB (3–5% portfolio) as a crisis optionality play: buy and finance with short 3–6 month 10% OTM calls (covered-call collar) to collect premium while keeping upside for opportunistic buyouts; exit/rehab if Berkshire tangible book value falls >10% or cash deployment pace remains nil over 6 months. Risk/reward skewed to protect capital and capture M&A optionality in a drawdown.
• Event-driven long VRTX via options (1–2% portfolio): purchase 9–15 month calls (or call spreads) to capture regulatory/late-stage kidney catalysts, paired with a 3–6 month SPY put (or put spread) sized to offset market beta. Upside is 3x+ on a positive approval/readout and limited to option premium on failure; hedge mitigates systemic drawdown risk during binary windows.
• Tactical macro hedge (0.5–1.5% portfolio cost): buy 3-month SPY put spreads (buy ~5% OTM, sell ~8–10% OTM) or a VIX call spread to protect against a rapid risk-off move tied to geopolitical escalation. This is an insurance trade — expect to pay ~0.5–1.5% of portfolio for 8–15% drawdown protection over the next quarter; unwind if oil volatility falls and the 2y yield retraces below recent highs.